- Home
- REE vs BCAB Comparison
REE vs BCAB Comparison
Compare REE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REE | BCAB |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 12.5M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REE | BCAB |
|---|---|---|
| Price | $0.60 | $0.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $11.75 | $1.00 |
| AVG Volume (30 Days) | 49.8K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.13 |
| 52 Week High | $6.60 | $1.43 |
Technical Indicators
Market Signals| Indicator | REE | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 38.09 |
| Support Level | $0.53 | $0.14 |
| Resistance Level | $0.75 | $0.27 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 40.08 | 11.00 |
Price Performance
Historical ComparisonAbout REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.